Exact Mass: 497.34812120000004
Exact Mass Matches: 497.34812120000004
Found 130 metabolites which its exact mass value is equals to given mass value 497.34812120000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(5Z,8Z,13E,15S)-11,12,15-Trihydroxyicosa-5,8,13-trienoylcarnitine
(5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,8Z,13E,15S)-11,12,15-trihydroxyicosa-5,8,13-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoylcarnitine
7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoylcarnitine
7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Nervonoyl Methionine
C29H55NO3S (497.39024400000005)
N-nervonoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Methionine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
2-((4R)-4-((3R,5R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-methylpentanamido)ethane-1-sulfonic acid
C27H47NO5S (497.31747720000004)
Ile Ile Pro Arg
C23H43N7O5 (497.33255080000004)
Ile Ile Arg Pro
C23H43N7O5 (497.33255080000004)
Ile Leu Pro Arg
C23H43N7O5 (497.33255080000004)
Ile Leu Arg Pro
C23H43N7O5 (497.33255080000004)
Ile Pro Ile Arg
C23H43N7O5 (497.33255080000004)
Ile Pro Leu Arg
C23H43N7O5 (497.33255080000004)
Ile Pro Arg Ile
C23H43N7O5 (497.33255080000004)
Ile Pro Arg Leu
C23H43N7O5 (497.33255080000004)
Ile Arg Ile Pro
C23H43N7O5 (497.33255080000004)
Ile Arg Leu Pro
C23H43N7O5 (497.33255080000004)
Ile Arg Pro Ile
C23H43N7O5 (497.33255080000004)
Ile Arg Pro Leu
C23H43N7O5 (497.33255080000004)
Leu Ile Pro Arg
C23H43N7O5 (497.33255080000004)
Leu Ile Arg Pro
C23H43N7O5 (497.33255080000004)
Leu Leu Pro Arg
C23H43N7O5 (497.33255080000004)
Leu Leu Arg Pro
C23H43N7O5 (497.33255080000004)
Leu Pro Ile Arg
C23H43N7O5 (497.33255080000004)
Leu Pro Leu Arg
C23H43N7O5 (497.33255080000004)
Leu Pro Arg Ile
C23H43N7O5 (497.33255080000004)
Leu Pro Arg Leu
C23H43N7O5 (497.33255080000004)
Leu Arg Ile Pro
C23H43N7O5 (497.33255080000004)
Leu Arg Leu Pro
C23H43N7O5 (497.33255080000004)
Leu Arg Pro Ile
C23H43N7O5 (497.33255080000004)
Leu Arg Pro Leu
C23H43N7O5 (497.33255080000004)
Pro Ile Ile Arg
C23H43N7O5 (497.33255080000004)
Pro Ile Leu Arg
C23H43N7O5 (497.33255080000004)
Pro Ile Arg Ile
C23H43N7O5 (497.33255080000004)
Pro Ile Arg Leu
C23H43N7O5 (497.33255080000004)
Pro Leu Ile Arg
C23H43N7O5 (497.33255080000004)
Pro Leu Leu Arg
C23H43N7O5 (497.33255080000004)
Pro Leu Arg Ile
C23H43N7O5 (497.33255080000004)
Pro Leu Arg Leu
C23H43N7O5 (497.33255080000004)
Pro Arg Ile Ile
C23H43N7O5 (497.33255080000004)
Pro Arg Ile Leu
C23H43N7O5 (497.33255080000004)
Pro Arg Leu Ile
C23H43N7O5 (497.33255080000004)
Pro Arg Leu Leu
C23H43N7O5 (497.33255080000004)
Arg Ile Ile Pro
C23H43N7O5 (497.33255080000004)
Arg Ile Leu Pro
C23H43N7O5 (497.33255080000004)
Arg Ile Pro Ile
C23H43N7O5 (497.33255080000004)
Arg Ile Pro Leu
C23H43N7O5 (497.33255080000004)
Arg Leu Ile Pro
C23H43N7O5 (497.33255080000004)
Arg Leu Leu Pro
C23H43N7O5 (497.33255080000004)
Arg Leu Pro Ile
C23H43N7O5 (497.33255080000004)
Arg Leu Pro Leu
C23H43N7O5 (497.33255080000004)
Arg Pro Ile Ile
C23H43N7O5 (497.33255080000004)
Arg Pro Ile Leu
C23H43N7O5 (497.33255080000004)
Arg Pro Leu Ile
C23H43N7O5 (497.33255080000004)
Arg Pro Leu Leu
C23H43N7O5 (497.33255080000004)
LPE O-19:0;O
C24H52NO7P (497.34812120000004)
(5Z,8Z,13E,15S)-11,12,15-Trihydroxyicosa-5,8,13-trienoylcarnitine
7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoylcarnitine
7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoylcarnitine
(4S,4aS,6aR,8R,9R,10aR,13R,14aS,18aR,18bR,E)-9-ethyl-4,8,19-trihydroxy-10a,12,13,18a-tetramethyl-2,3,4,4a,6a,7,8,9,10,10a,13,14,18a,18b-tetradecahydro-14a,17-(metheno)benzo[b]naphtho[2,1-h][1]azacyclododecine-16,18(1H,15H)-dione
C30H43NO5 (497.31410680000005)
1-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(pyridin-2-ylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(pyridin-3-ylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(pyridin-3-ylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-4-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-4-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
2-((4R)-4-((3R,5R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-methylpentanamido)ethane-1-sulfonic acid
C27H47NO5S (497.31747720000004)
1-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(3-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-4-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-4-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-4-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-4-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
1-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-4-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propylurea
3-((2E,7S,8E,10E,13R,14R,16E,18E)-14-ethyl-7,13-dihydroxy-2,16,18-trimethylicosa-2,8,10,16,18-pentaenoyl)-4-hydroxy-5-methylene-1,5-dihydro-2H-pyrrol-2-one
C30H43NO5 (497.31410680000005)
3-((1R,2R,4aS,5S,8aR)-2-((2R,3R,5E,7E)-3-ethyl-2-hydroxy-5,7-dimethylnona-5,7-dien-1-yl)-5-hydroxy-1-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl)-4-hydroxy-5-methylene-1,5-dihydro-2H-pyrrol-2-one
C30H43NO5 (497.31410680000005)
(6Z,9Z,12Z,15Z,18Z,21Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]tetracosa-6,9,12,15,18,21-hexaenamide
C32H51NO3 (497.38687360000006)
(4Z,7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]docosa-4,7,10,13,16,19-hexaenamide
C32H51NO3 (497.38687360000006)
(4Z,7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]hexadeca-4,7,10,13-tetraenamide
C32H51NO3 (497.38687360000006)
(6Z,9Z,12Z,15Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]octadeca-6,9,12,15-tetraenamide
C32H51NO3 (497.38687360000006)
(3Z,6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]octadeca-3,6,9,12,15-pentaenamide
C32H51NO3 (497.38687360000006)
(5Z,8Z,11Z,14Z,17Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]icosa-5,8,11,14,17-pentaenamide
C32H51NO3 (497.38687360000006)
2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyundecane-1-sulfonic acid
C27H47NO5S (497.31747720000004)
(4E,8E,12E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tetradeca-4,8,12-triene-1-sulfonic acid
C27H47NO5S (497.31747720000004)
(E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid
C27H47NO5S (497.31747720000004)
1-(2-methoxy-octadecanyl)-sn-glycero-3-phosphoethanolamine
C24H52NO7P (497.34812120000004)
18-o-methyldelterine
{"Ingredient_id": "HBIN002146","Ingredient_name": "18-o-methyldelterine","Alias": "NA","Ingredient_formula": "C26H43NO8","Ingredient_Smile": "CCN1CC2(CCC(C34C2C(C(C31)(C5(CC(C6CC4(C5C6OC)O)OC)O)O)OC)OC)COC","Ingredient_weight": "497.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "14279","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101232078","DrugBank_id": "NA"}